IRAK4-IN-16 is a potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associate kinase-4 (IRAK4). References: Cheng BY, Lau EY, Leung HW, Leung CO, Ho NP, Gurung S, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res. 2018 Feb 26. pii: canres.2445.2017. doi: 10.1158/0008-5472.CAN-17-2445. [Epub ahead of print] PubMed PMID: 29483095.

纯度：≥98%

CAS：509093-72-5